Press Releases
Page 8 • 12 itemsAccess critical pharma & biotech press releases. Stay ahead on drug approvals, clinical trials, M&A, and regulatory updates impacting global markets.
Femasys Launches FemaSeed Complete Fertility Solution for OB/GYNs at ACOG 2026
Femasys Inc. launches FemaSeed Complete at ACOG 2026, enabling OB/GYNs to perform first-line fertility insemination in their practices for 10M infertile women.
Mauna Kea Technologies Secures CE Mark Under New MDR, Expands European Medical Device Approvals
Mauna Kea Technologies obtains CE Mark under new Medical Device Regulation and regulatory approvals in UK and Switzerland, marking significant expansion.
Pembrolizumab Plus Lenvatinib Shows Promise for Rare Clear Cell Gynecological Cancers in Phase 2 Trial
LARA Phase 2 trial published in The Lancet Oncology demonstrates promising clinical activity of pembrolizumab plus lenvatinib for recurrent clear cell cancers.
Roche's Gazyva Receives FDA Acceptance for Lupus Treatment Following Positive Phase III Trial Results
FDA accepts Roche's supplemental application for Gazyva (obinutuzumab) in systemic lupus erythematosus based on positive ALLEGORY study results.
Dupixent Becomes First Biologic Approved for Chronic Spontaneous Urticaria in Children Ages 2-11
Sanofi and Regeneron's Dupixent receives FDA approval as the first biologic treatment for pediatric chronic spontaneous urticaria in children 2-11 years old.
Ipsen Receives EU Approval for Ojemda (Tovorafenib) to Treat Pediatric Brain Cancer with BRAF Mutations
Ipsen secures conditional EU marketing authorization for Ojemda (tovorafenib) to treat pediatric low-grade glioma with BRAF alterations in patients 6 months and older.
RedHill's Opaganib Shows Promise in Neuroblastoma and Triple-Negative Breast Cancer Studies at AACR 2026
RedHill's opaganib demonstrates enhanced efficacy in neuroblastoma chemotherapy combinations and improved anti-tumor immunity in TNBC preclinical studies.
RedHill's Opaganib Shows Promise in Neuroblastoma and Triple-Negative Breast Cancer Studies at AACR 2026
RedHill's opaganib demonstrates enhanced efficacy in neuroblastoma chemotherapy combinations and improved anti-tumor immunity in preclinical cancer studies.
SAB Biotherapeutics SAB-142 Shows C-Peptide Preservation in Type 1 Diabetes Phase 1 Trial
SAB-142 preserved C-peptide in all 4 Type 1 diabetes patients, with 3 showing super responder profiles and improved glycemic control in Phase 1 trial.
Boston Scientific Reports Strong Q1 2026 Growth with 10.9% US Sales Increase and Clinical Trial Breakthroughs
Boston Scientific delivers robust Q1 2026 performance with double-digit growth across all regions and presents breakthrough clinical trial data at major conference.
CervoMed's Neflamapimod Shows Brain Volume Increase in Dementia with Lewy Bodies Trial at AAN 2026
CervoMed reports neflamapimod increased basal forebrain volume and connectivity in DLB patients, suggesting potential disease reversal in early stages.
CervoMed's Neflamapimod Shows Brain Volume Improvements in Dementia with Lewy Bodies at AAN 2026
CervoMed reports neflamapimod increased basal forebrain volume in DLB patients, suggesting potential disease reversal in early neurodegenerative stages.